Crystal Taylor
Family · Waycross, GANPI 1740555705
Payments from drug & device makers
Across 620 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Otsuka America Pharmaceutical, Inc.$646
- Lilly USA, LLC$616
- Pfizer$545
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$519
- plus $5K from 52 others
What the payments were for
- Food & beverage$10,450100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,450 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 153 | $182,300 |
| OzempicSemaglutide | 121 | $147,995 |
| JanuviaSitagliptin Phosphate | 81 | $98,805 |
| LinzessLinaclotide | 94 | $95,858 |
| JardianceEmpagliflozin | 84 | $89,979 |
| EliquisApixaban | 85 | $85,020 |
| RexultiBrexpiprazole | 49 | $76,321 |
| VraylarCariprazine Hcl | 44 | $69,568 |
| FarxigaDapagliflozin Propanediol | 80 | $62,872 |
| RybelsusSemaglutide | 34 | $45,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $43,237 |
| MyrbetriqMirabegron | 53 | $35,014 |
| TrulicityDulaglutide | 21 | $33,927 |
| TradjentaLinagliptin | 45 | $31,272 |
| XareltoRivaroxaban | 16 | $26,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $616 | $216,227174 claims |
| Novo NordiskOzempic, Rybelsus | $1,320 | $193,869155 claims |
| AbbVieLinzess, Vraylar, Synthroid | $1,332 | $168,880171 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $269 | $129,231142 claims |
| PfizerEliquis, Nurtec Odt | $545 | $105,966100 claims |
| MerckJanuvia | $245 | $98,80581 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $195 | $92,320131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $646 | $76,32149 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $189 | $56,22265 claims |
| Astellas Pharma US IncMyrbetriq | $271 | $35,01453 claims |
| Johnson & JohnsonXarelto | $120 | $26,40516 claims |
| Sanofi-aventis U.S. LLCMultaq | $63 | $12,83316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Waycross
- Hannah BanachWaycross$85K
- Tiffany HarkleroadWaycross$16K
- Morgan EldridgeWaycross$15K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.